SB-612,111 is an opioid receptor ligand which is a potent and selective antagonist for the nociceptin receptor (ORL-1), several times more potent than the older drug J-113,397.[1] It does not have analgesic effects in its own right, but prevents the development of hyperalgesia,[2] and also shows antidepressant effects in animal studies.[3]

See also

References

  1. ^ Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, et al. (June 2007). "Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 961–7. doi:10.1124/jpet.106.116764. PMID 17329552. S2CID 17504101.
  2. ^ Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, et al. (February 2004). "Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)". The Journal of Pharmacology and Experimental Therapeutics. 308 (2): 454–61. doi:10.1124/jpet.103.055848. PMID 14593080. S2CID 8036750.
  3. ^ Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, et al. (June 2007). "Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 968–74. doi:10.1124/jpet.106.116780. PMID 17329551. S2CID 2557475.